- Home
- DTF vs UNCY Comparison
DTF vs UNCY Comparison
Compare DTF & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTF
- UNCY
- Stock Information
- Founded
- DTF 1991
- UNCY 2016
- Country
- DTF United States
- UNCY United States
- Employees
- DTF N/A
- UNCY N/A
- Industry
- DTF Investment Managers
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- DTF Finance
- UNCY Health Care
- Exchange
- DTF Nasdaq
- UNCY Nasdaq
- Market Cap
- DTF 78.2M
- UNCY 71.3M
- IPO Year
- DTF N/A
- UNCY 2021
- Fundamental
- Price
- DTF $11.19
- UNCY $0.76
- Analyst Decision
- DTF
- UNCY Strong Buy
- Analyst Count
- DTF 0
- UNCY 4
- Target Price
- DTF N/A
- UNCY $6.38
- AVG Volume (30 Days)
- DTF 21.1K
- UNCY 1.6M
- Earning Date
- DTF 01-01-0001
- UNCY 05-14-2025
- Dividend Yield
- DTF 3.64%
- UNCY N/A
- EPS Growth
- DTF N/A
- UNCY N/A
- EPS
- DTF 0.44
- UNCY N/A
- Revenue
- DTF N/A
- UNCY N/A
- Revenue This Year
- DTF N/A
- UNCY N/A
- Revenue Next Year
- DTF N/A
- UNCY $1,458.53
- P/E Ratio
- DTF $24.34
- UNCY N/A
- Revenue Growth
- DTF N/A
- UNCY N/A
- 52 Week Low
- DTF $10.29
- UNCY $0.20
- 52 Week High
- DTF $11.19
- UNCY $0.96
- Technical
- Relative Strength Index (RSI)
- DTF 52.43
- UNCY 69.71
- Support Level
- DTF $11.14
- UNCY $0.56
- Resistance Level
- DTF $11.21
- UNCY $0.62
- Average True Range (ATR)
- DTF 0.05
- UNCY 0.06
- MACD
- DTF 0.00
- UNCY 0.01
- Stochastic Oscillator
- DTF 55.00
- UNCY 79.03
About DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.